Medchemexpress LLC Zelebrudomide (NX-2127) | 2416131-46-7 | C39H45N9O5 | 100 MG

Supplier:  Medchemexpress LLC HY153220100MG

Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (BTK). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. Zelebrudomide also catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with respective values of 25 nM and 54 nM. Additionally, it stimulates T cell activation and increases IL-2 production in primary human T Cells.

• Orally active PROTAC degrader targets Bruton's Tyrosine Kinase (BTK).
• Inhibits proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib.
• Catalyzes degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with respective values of 25 nM and 54 nM.
• Stimulates T cell activation and increases IL-2 production in primary human T Cells.
• Demonstrates potent degradation of BTK in vivo.
• Results in superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice.

Catalog No. 50-003-72571